Klineo
Bridge the gap between patients and clinical research.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | €2.0m | Early VC | |
| Total Funding | 000k | ||
| USD | 2023 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| Profit | 0000 |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Dealroom estimates
Related Content
Klineo is a digital health company addressing the challenge of patient recruitment for oncology clinical trials. Founded in 2021 by a multidisciplinary team including medical oncologist Dr. Arnaud Bayle and two engineers from École Polytechnique, Thomas Peyresblanques (CEO) and Nicolas Drizard (CTO), the company aims to simplify the complex process of finding suitable clinical trials for both patients and physicians. The founding was driven by Dr. Bayle's first-hand experience at the Gustave Roussy Institute with the difficulties in matching patients to the more than 3,000 ongoing oncology trials in France.
The company operates a platform that uses AI-powered algorithms to connect doctors and patients with relevant clinical trials in under a minute. The service features two distinct interfaces, one for patients and one for healthcare professionals. Users can create a profile with specific medical information, and the platform's matching algorithms compare this data against the inclusion and exclusion criteria of a comprehensive, real-time database of all clinical trials open in France. The platform is free for patients and doctors; Klineo's revenue is generated through partnerships with industrial sponsors and academic institutions, such as Pfizer, AstraZeneca, and Unicancer, who benefit from more efficient patient recruitment.
A significant milestone was a 2022 pilot project at the Gustave Roussy Institute, which led to the launch of a national platform for triple-negative breast cancer in collaboration with the patient association Collectif Triplettes Roses. In 2023, the platform expanded to include breast, skin, and lymphoma cancers. In April 2024, Klineo secured €2 million in a seed funding round from Bpifrance and business angels. This capital is intended to expand the platform's coverage to all cancer types in France by the end of 2024, with future plans to extend into other European countries, the US, and other disease areas like rare and neurological diseases.
Keywords: clinical trial recruitment, oncology, healthtech, patient matching, AI in healthcare, digital health platform, cancer research, medical technology, Gustave Roussy, Bpifrance, Unicancer, Pfizer, AstraZeneca, Thomas Peyresblanques, Nicolas Drizard, Dr. Arnaud Bayle, clinical trial search, patient access, therapeutic innovation, real-time trial updates, oncology data management